Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Aug 2013 16:02

RNS Number : 0303M
Skyepharma PLC
19 August 2013
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Skyepharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

On market transfer between direct and indirect funds

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Chase (GA Group) Nominees Limited 637,000

 

Chase Nominees Limited 98,418

 

Vidacos Nominees Limited 807,000

* denotes direct interest

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

16 August 2013

6. Date on which issuer notified:

19 August 2013

7. Threshold(s) that is/are crossed orreached: vi, vii

3% to

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares GBP1GB00B3BFNB64

 

 

 

1,542,418

 

1,542,418

1,542,418

Nil Held

1,542,418

Nil Held

3.34%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,542,418

3.34%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

 

 

 

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

 

13. Additional information:

Aviva have notified a change in the nature of their holdings from direct to indirect holdings, no change in percentage of shares held.

 

14. Contact name:

J Murphy

15. Contact telephone number:

020 7881 1172

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEKLFFXVFBBBF
Date   Source Headline
3rd Apr 201411:51 amRNSDirector/PDMR Shareholding
3rd Apr 201411:50 amRNSDirector/PDMR Shareholding
1st Apr 20144:58 pmRNSAnnual Financial Report
31st Mar 20147:45 amRNSProposed Placing and Open Offer to Raise £112m
31st Mar 20147:00 amRNSFinal Results
26th Mar 20147:00 amRNSNotice of Results
6th Mar 20142:44 pmRNSDirector Declaration
5th Mar 20147:00 amRNSBoard Changes
4th Mar 20149:47 amRNSHolding(s) in Company
3rd Mar 20143:38 pmRNSHolding(s) in Company
28th Feb 20147:02 amRNSBoard Change
21st Feb 20142:53 pmRNSAnoro Receives Positive Opinion from CHMP
10th Feb 20145:59 pmRNSHolding(s) in Company
10th Feb 20147:00 amRNSflutiform launched in France
4th Feb 20143:19 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSTrading Update
22nd Jan 20142:50 pmRNSPositive step towards flutiform approval in Spain
19th Dec 20137:45 amRNSANORO ELLIPTA RECEIVES REGULATORY APPROVAL IN US
18th Dec 20132:52 pmRNSUpdate on Lyon manufacturing facility
4th Dec 20137:00 amRNSCapital Markets meeting & flutiform sales update
25th Nov 20135:54 pmRNSDirector/PDMR Shareholding
25th Nov 201310:57 amRNSFurther re Directorate Change
19th Nov 20137:00 amRNSPartner Kyorin launches flutiform in Japan
11th Nov 201311:41 amRNSHolding(s) in Company
11th Nov 201310:42 amRNSDirector/PDMR Shareholding
30th Oct 201311:38 amRNSHolding(s) in Company
10th Oct 20137:00 amRNSInterim Management Statement
24th Sep 20133:39 pmRNSHolding(s) in Company
23rd Sep 20134:31 pmRNSHolding(s) in Company
23rd Sep 20139:31 amRNSHolding(s) in Company
20th Sep 20138:39 amRNSCapital Markets Day, Muttenz, Switzerland
20th Sep 20138:20 amRNSRELVAR ELLIPTA Receives Approval in Japan
20th Sep 20137:00 amRNSflutiform approved in Japan
19th Sep 20132:02 pmRNSHolding(s) in Company
19th Sep 20131:54 pmRNSHolding(s) in Company
19th Sep 20137:00 amRNSflutiform trial for COPD initiated in Europe
22nd Aug 201311:11 amRNSAppointment of Andrew Derodra as CFO
19th Aug 20134:02 pmRNSHolding(s) in Company
15th Aug 20135:20 pmRNSDirector/PDMR Shareholding
15th Aug 20137:00 amRNSHalf Yearly Report
14th Aug 20133:38 pmRNSHolding(s) in Company
1st Aug 20134:08 pmRNSHolding(s) in Company
31st Jul 20139:28 amRNSflutiform recommended for approval in Japan
8th Jul 20137:00 amRNSNotice of Results
20th Jun 201311:00 amRNSflutiform launch in Italy
19th Jun 201312:31 pmRNSHolding(s) in Company
10th Jun 201310:35 amRNSHolding(s) in Company
4th Jun 20134:40 pmRNSSecond Price Monitoring Extn
4th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20137:00 amRNSPresenting at Jefferies 2013 Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.